Side-by-side comparison of AI visibility scores, market position, and capabilities
Chicago packaged frozen food brands (NYSE: CAG) ~$11.9B FY2025 revenue; Birds Eye 40%+ frozen veggie share, Slim Jim #1 convenience meat snack, Pinnacle Foods acquisition 2018 competing with Nestlé and General Mills.
Conagra Brands, Inc. is a Chicago, Illinois-based packaged food company — publicly traded on the New York Stock Exchange (NYSE: CAG) as an S&P 500 Consumer Staples component — marketing a portfolio of branded consumer foods and foodservice products including frozen meals (Birds Eye, Healthy Choice, Marie Callender's, Banquet), condiments and sauces (Hunt's, Slim Jim, Duncan Hines, Vlasic), snacks (Angie's BOOM CHICKA POP, Bigs seeds, Orville Redenbacher's), and international brands through approximately 18,000 employees. In fiscal year 2025 (ending May 2025), Conagra reports revenues of approximately $11.9 billion, navigating consumer trade-down behavior (consumers buying fewer premium branded frozen meals and choosing lower-price options or home-cooked meals) and competitive private label penetration in frozen meal categories (Birds Eye, Healthy Choice, and Marie Callender's facing increased competition from Kroger, Walmart, and Costco private label frozen meal options priced 20-30% below branded alternatives). CEO Sean Connolly has executed Conagra's "Conagra Way" transformation: divesting commodity businesses (Lamb Weston potato processing — spun off as independent public company in 2016; private label operations sold) and building the brand portfolio through the 2018 acquisition of Pinnacle Foods ($10.9 billion — adding Birds Eye, Duncan Hines, Vlasic, and Gardein plant-based foods) — concentrating Conagra's capital and marketing investment on premium branded frozen and packaged food categories where Conagra holds #1 or #2 market share positions. Conagra's frozen vegetable leadership (Birds Eye — 40%+ US frozen vegetable market share) and frozen meal portfolio (Healthy Choice café steamers, Marie Callender's pot pies and dinners) position the company in categories that benefit from the "cooking-at-home" preference when dining out costs rise.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.